Get the Daily Brief
Latest Biotech News
Immune-oncology convenience strategy posts early small-cell data
Amid the push for easier administration in immunotherapy, Ambrx/Ambrx?—the program described here—reported early safety and activity for subcutaneous tarlatamab in extensive-stage small cell lung...
Precision immunotherapy combinations face mixed performance in lung cancer
A closely watched Phase 3 strategy pairing an antibody-drug conjugate with an immune checkpoint inhibitor in PD-L1-high metastatic lung cancer fell short. Sacituzumab govitecan, combined with...
Imaging advances: faster, more reliable digital pathology and membrane analysis
Two methods aimed at accelerating biomarker discovery moved closer to practical lab workflows. Helmholtz Munich, TUM, and the University of Basel introduced MemBrain v2, an AI tool that automates...
Diagnostics and device innovation for point-of-care performance
Interra Health said it is expanding access to GLP-1 medications for Medicare patients via a $50-per-month Bridge program support offering. Separately, new sensor approaches continue pushing...
AI for protein understanding scales genomics-era bottlenecks
A new AI method claims to map the protein universe in a single view, aiming to compress how researchers relate protein families and their evolutionary relationships—an approach that could improve...
Data-driven oncology care: better staging signals and treatment targeting
A new real-world outcomes thread emphasized the need to verify whether therapies reach their intended targets. In imaging-led work, researchers described approaches intended to show whether...
Regulatory and evidence quality signals: corrections and trial critique
Concerns around dosing biomarkers and scientific-method reliability continued to surface. A translational modeling study argued that receptor occupancy may not reliably predict immune activation...
Funding and platform scaling: AI in health-adjacent innovation
Inspiren secured $70 million in Series C funding led by NewView Capital to scale its AI-powered senior living platform. The system relies on ambient sensors and computer vision to predict falls...
Corporate venture capital reshapes biopharma financing dynamics
Corporate venture capital is increasingly becoming a structural part of biopharma ownership and follow-on funding, according to commentary featuring UK and Nordic investor perspectives. British...
Phase 3 oncology disappointment and downstream corporate pressure
Novartis’ neuromuscular RNA therapeutics program ran into a major setback as delpacibart etedesiran (del-desiran) failed to hit its primary endpoint in the pivotal HARBOR Phase III trial,...
AI-driven membrane mapping for faster cell biology workflows
MemBrain v2, an AI tool developed by teams at Helmholtz Munich, Technical University of Munich (TUM), and the University of Basel’s Biozentrum, is automating 3D membrane mapping workflows that...
Cancer immunotherapy dosing model challenges a key biomarker assumption
A translational modelling study published in the British Journal of Cancer is challenging a foundational assumption in pembrolizumab dosing: that receptor occupancy of PD-1 on T cells directly...
Targeted immunotherapy or ADC combinations fail to improve outcomes in PD-L1-high lung cancer
Sacituzumab govitecan, an antibody-drug conjugate, underperformed in a Phase 3 setting when combined with pembrolizumab in PD-L1-high metastatic lung cancer. The development reported in a closely...
Early clinical signal for tarlatamab and regimen flexibility in small cell lung cancer
In small cell lung cancer, subcutaneous tarlatamab (from the DeLLphi-308 Phase 1b study) showed safety and early activity, expanding options for patients after platinum-based chemotherapy....
Sangamo-like engineering in solid tumors: ICOS-enhanced T-cell receptors
Engineered T cell receptors with built-in ICOS signaling (a co-stimulatory pathway) are reported to generate longer-lasting anti-tumor activity in adoptive cell therapy, according to research...
Pancreatic cancer platform: new vein-based diagnostic approach in hard-to-sample cases
A case report highlights a procedural innovation for pancreatic tumor diagnosis and treatment planning when standard tissue sampling pathways are unsafe. The report describes how doctors reached a...
Kidney disease management: real-world evidence for Nefecon in IgA nephropathy
A real-world study reports that Nefecon (targeted-release budesonide) reduced proteinuria and helped preserve kidney function in primary IgA nephropathy. The analysis also includes patients...
Antibody-Drug Conjugates meet cost-effectiveness in MSI-high colorectal cancer
A health economic analysis concludes that nivolumab plus ipilimumab can be more cost-effective than pembrolizumab for metastatic MSI-high or mismatch repair-deficient colorectal cancer. The study,...
Antibiotic resistance in gonorrhea: surveillance signals shift genetically
Research reviewed in the context of global antimicrobial resistance points to shifting genetic patterns in Neisseria gonorrhoeae associated with azithromycin resistance, complicating molecular...
Late-stage neuromuscular pipeline setback and investor pressure at Novartis
Novartis disclosed that its neuromuscular candidate delpacibart etedesiran failed a pivotal Phase III trial, delivering a major blow to the company’s late-stage execution. In the HARBOR study...